Simcere Pharmaceutical Group (NYSE:SCR)
| CAPS Rating |
|
|---|
SCR
VS S&P 500 (SPY)
SCR News and Commentary
- Simcere Pharmaceutical Group Increases Sales but Misses Revenue Estimate – The Motley Fool
- BMY Inks Deal with Chinese University - Analyst Blog – NASDAQ
- Simcere Misses on all Fronts - Analyst Blog – NASDAQ
- Cummins Buys SCR Doser Technology - Analyst Blog – NASDAQ
- Delaware Judge Says BofA Can Offer $20 Million Lawsuit Settlement For NY Approval -Bloomberg – SmartMoney
- AGCO Corp. Beats, Ups Guidance - Analyst Blog – NASDAQ
- Don't Get Too Worked Up Over Simcere Pharmaceutical Group's Earnings – The Motley Fool
- Revenues Decline at Simcere Pharma - Analyst Blog – NASDAQ
- Simcere Pharmaceutical Group Crushes Earnings Estimates – The Motley Fool
How do you think SCR will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
231
Outperform
10
Underperform
All-Star Players
37
Outperform
3
Underperform
Wall Street
2
Outperform
1
Underperform
RSS Headlines
Fool UK
